Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis

Abstract Background Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance. Methods We established a bio-bank of human PDAC organoid models, cov...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Tianxing Zhou, Yongjie Xie, Xupeng Hou, Weiwei Bai, Xueyang Li, Ziyun Liu, Quan Man, Jingyan Sun, Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yifei Wang, Hongwei Wang, Wenna Jiang, Song Gao, Tiansuo Zhao, Antao Chang, Xiuchao Wang, Hongxia Sun, Xiufeng Zhang, Shengyu Yang, Chongbiao Huang, Jihui Hao, Jing Liu
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2023-05-01
Цуврал:	Journal of Experimental & Clinical Cancer Research
Нөхцлүүд:	Pancreatic cancer Organoids High-throughput drug screening c-Jun Irbesartan
Онлайн хандалт:	https://doi.org/10.1186/s13046-023-02671-8
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!